Presentations & Videos by Rebiotix

The following is a list of presentations and videos by Rebiotix Inc., a Ferring Company.

Lee Jones Radio Interview at Health Nerd on Rebiotix

Health Nerd

Radio Broadcast Date: February 18, 2016

Summary: Rebiotix CEO Lee Jones discusses the company’s progress in commercializing a next-generation FMT for the treatment of recurrent Clostridium difficile infection with WFME health reporter Abe Aboraya. She explains that Rebiotix recently completed a randomized, double-blinded, placebo controlled study and outlines the process of obtaining regulatory approval to market a biological drug based on the human gut microbiota

Listen to the audio of this broadcast (MP3)

New Product In Development Looks To Help Patients With Clostridium Difficile

Broadcast date:  Jan. 11, 2016

In this episode of DeviceTalks, publisher Brian Johnson discusses the Rebiotix mission of harnessing the power of the human microbiome to combat challenging diseases including Clostridium difficile infection and the differences between running a medtech company and a biotech company with Lee Jones, CEO of Rebiotix Inc.

Business, Regulatory and Clinical Challenges in Commercializing a Microbiota Based Drug

Presented: October 23, 2015

Summary: Rebiotix President and CEO Lee Jones discussed the challenging landscape for commercializing microbiota-based drugs using the company’s Microbiota Restoration Therapy™ (MRT™) drug platform as an example at the World Congress on Targeting the Microbiota held October 21-23, 2015 at the Institute Pasteur in Paris, France. The third annual conference focused on current advances in knowledge about the role of the microbiota in health and disease including methods, industrial innovations and regulatory issues.

Download this presentation (24 MB)

New Product In Development Looks To Help Patients With Clostridium Difficile

Broadcast date:  Oct 19, 2015 (ID Week)

In the world of gastrointestinal conditions clostridium difficile, or C. diff. is becoming a more common condition confronting doctors. Finding the best treatment method remains to be seen.

Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine discussed the development of one such potential treatment option being developed during the annual ID Week conference in San Diego.

Harnessing the Gut Microbiome: Separating the Hype from the Evidence

Presented September 22, 2015

Summary: Rebiotix President and CEO Lee Jones discussed the need for clinical trials that generate medical-based scientific evidence through FDA approval process in order to providing wide access to potentially lifesaving microbiota-based drugs. Jones presented at the inaugural Targeting the Microbiome conference held September 22-23, 2015 in Boston, MA. The conference, sponsored by the Cambridge Healthtech Institute, focused on scientific and clinical research and applications in microbial targeted therapies for inflammation, metabolic disorders, immune disorders and other indications.

Download this presentation (3 MB)

Interview with Lee Jones, CEO of Rebiotix on GMSP Business

Broadcast date:  Nov 4, 2013 (KSTP Ch. 5)

“You may have read or seen information about a medical procedure called fecal transplant. It’s what it sound like — feces transplanted in the human digestive system as a treatment for severe gastrointestinal disease. The Rebiotix company in Roseville is developing a new generation of this treatment — a micro-biotic therapy that it hopes will deliver results without the unpleasantness.”

“Harnessing the Power of the Human Microbiome”

Presented: May 03, 2013

Summary: Rebiotix CEO Lee Jones discussed the challenges and opportunities involved in the company’s plans to develop a biologic drug for the treatment of recurrent Clostridium difficile infection in a presentation at an FDA public workshop on fecal microbiota for transplantation held May 2-3 in Washington, D.C.

Download this presentation (291 KB)

Read the complete transcripts of the workshop sponsored by the Center for Biologics Evaluation and Research on May 2 and 3, 2013 (See the Resources for You).